Zimmer Biomet Holdings, Inc. Stock price

Equities

ZBH

US98956P1021

Medical Equipment, Supplies & Distribution

Real-time Estimate Cboe BZX 10:06:04 2024-03-01 am EST 5-day change 1st Jan Change
124.2 USD -0.16% Intraday chart for Zimmer Biomet Holdings, Inc. -3.65% +2.28%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Enjoy this offer
* See conditions on site
Sales 2024 * 7.74B Sales 2025 * 8.1B Capitalization 25.5B
Net income 2024 * 1.05B Net income 2025 * 1.2B EV / Sales 2024 * 3.8 x
Net Debt 2024 * 3.91B Net Debt 2025 * 2.61B EV / Sales 2025 * 3.47 x
P/E ratio 2024 *
23.8 x
P/E ratio 2025 *
21.2 x
Employees 18,000
Yield 2024 *
0.78%
Yield 2025 *
0.84%
Free-Float 64.89%
More Fundamentals * Assessed data
Dynamic Chart
Zimmer Biomet's ROSA Shoulder Replacement Platform Receives FDA Clearance MT
Zimmer Biomet Holdings, Inc. Announces U.S. Food and Drug Administration 510(K) Clearance of the Rosa® Shoulder System for Robotic-Assisted Shoulder Replacement Surgery CI
Zimmer Biomet Maintains Quarterly Dividend at $0.24 a Share, Payable by April 30 to Shareholders of Record March 29 MT
Zimmer Biomet Holdings, Inc. Announces Quarterly Cash Dividend for the First Quarter of 2024, Payable on or About April 30, 2024 CI
Smith & Nephew Q4 Margin in Focus, Outlook Upgrade Likely, RBC Says MT
Zimmer Biomet Holdings, Inc. Showcases Latest Innovations Across Comprehensive Portfolio at AAOS 2024 Annual Meeting CI
UBS Adjusts Zimmer Biomet Price Target to $109 From $105, Maintains Sell Rating MT
Deutsche Bank Adjusts Zimmer Biomet Price Target to $140 From $147, Maintains Hold Rating MT
Zimmer Biomet Seeks M&A CI
Transcript : Zimmer Biomet Holdings, Inc., Q4 2023 Earnings Call, Feb 08, 2024
Zimmer Biomet forecasts upbeat 2024 profit on steady medical devices demand RE
Zimmer Biomet Q4 Adjusted Earnings, Net Sales Increase; Issues 2024 Guidance MT
(ZBH) ZIMMER BIOMET HOLDINGS Expects Fiscal Year 2024 EPS Range $8.00 - $8.15 MT
Earnings Flash (ZBH) ZIMMER BIOMET HOLDINGS Posts Q4 Revenue $1.94B, vs. Street Est of $1.93B MT
Earnings Flash (ZBH) ZIMMER BIOMET HOLDINGS Reports Q4 EPS $2.20, vs. Street Est of $2.16 MT
More news
1 day-0.16%
1 week-3.65%
Current month+0.09%
1 month-2.18%
3 months+5.51%
6 months+4.20%
Current year+2.28%
More quotes
1 week
122.90
Extreme 122.895
129.20
1 month
119.13
Extreme 119.13
129.52
Current year
119.13
Extreme 119.13
129.52
1 year
102.00
Extreme 102
149.25
3 years
100.39
Extreme 100.39
180.36
5 years
74.37
Extreme 74.37
180.36
10 years
74.37
Extreme 74.37
180.36
More quotes
Managers TitleAgeSince
Chief Executive Officer 48 18-10-31
Director of Finance/CFO 55 19-06-30
Chief Tech/Sci/R&D Officer - 21-06-06
Members of the board TitleAgeSince
Director/Board Member 68 06-12-31
Director/Board Member 68 08-12-31
Director/Board Member 51 14-12-11
More insiders
Date Price Change Volume
24-03-01 124.4 +0.02% 46 874
24-02-29 124.4 +0.19% 2,415,826
24-02-28 124.1 -1.77% 1,415,737
24-02-27 126.4 -0.40% 840,233
24-02-26 126.9 -1.78% 1,659,666

Delayed Quote Nyse, March 01, 2024 at 09:51 am EST

More quotes
Zimmer Biomet Holdings, Inc. specializes in designing, manufacturing, and selling orthopedic and dental reconstruction implants, spinal implants, and traumatology products. Net sales break down by family of products as follows: - reconstruction implants (57.5%): knees replacement (58.8% of net sales), hips replacement (41.2%); - surgical products and traumatology equipment (22.1%); - dental, spinal and craniomaxillofacial implants (12.8%); - other (7.6%): primarily orthopedic surgery materials and instruments used during post-operative rehabilitation. At the end of 2021, the group had approximately 30 production sites worldwide. Net sales are distributed geographically as follows: Americas (61.3%), Europe/Middle East/Africa (21.3%) and Asia/Pacific (17.4%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
124.4 USD
Average target price
136.1 USD
Spread / Average Target
+9.45%
Consensus
  1. Stock
  2. Equities
  3. Stock Zimmer Biomet Holdings, Inc. - Nyse
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.
SIGN UP NOW